---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016108"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:12:18.057238+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start

## Summary
- FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).
- Phase 1 trial will evaluate LNCB74 for multiple cancers.
- LNCB74 developed in partnership with LigaChem Biosciences under co-development agreement.
- NextCure CEO Michael Richman highlighted differentiation from other B7-H4 ADCs.
- IND acceptance allows NextCure to proceed with clinical development.

## SEC filing metadata
- accession: 0001558370-24-016108
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837024016108/0001558370-24-016108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837024016108/nxtc-20241210x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016108
- JSON: https://secwatch.observer/filing/0001558370-24-016108.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.